Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs MGM Resorts International (MGM) Price & Performance

Quest Diagnostics IncTrade
MGM Resorts InternationalTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs MGM Resorts International — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while MGM Resorts International trades at $46.73 (market cap $11.94B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.

DGXMGM
Market Cap
$22.80B$11.94B
Sector
HealthConsumer Cyclical
52-Week High
$216.02$50.69
52-Week Low
$166.42$30.72
Enterprise Value
$28.82B$40.98B
Dividend Yield
1.67%0.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.

DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.

MGM Resorts International

MGM Resorts International (MGM) trades at $47.24, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $48.93. Recent financials show revenue growth to $17.54B in 2025, though net income margin remains thin at 1.03%. The stock is buoyed by acquisition talks with Barry Diller's People Inc. at $48.30 per share, as reported by The Wall Street Journal on July 10, 2026, and positive cash flow projections for 2026.

Outlook: MGM offers moderate upside potential driven by acquisition interest and steady revenue, but risks include volatile earnings, high debt, and regulatory scrutiny. Investors should weigh the takeover premium against fundamental weakness in profitability and execution risks in the competitive casino sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About MGM Resorts International

MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.

Read more on MGM